Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties: Endocrinology

Absence of late recurrences in patients with a negative first follow-up after I-131 ablation for differentiated thyroid carcinoma

Frederik Verburg, Christian Dueren, Robbert Verkooijen, Markus Luster, Johannes van Isselt, Christoph Reiners and Marcel Stokkel
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 17P;
Frederik Verburg
1Nuclear Medicine, UMC Utrecht, Utrecht, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Dueren
2Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robbert Verkooijen
1Nuclear Medicine, UMC Utrecht, Utrecht, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Luster
2Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes van Isselt
1Nuclear Medicine, UMC Utrecht, Utrecht, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Reiners
2Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Stokkel
3Radiology, Division of Nuclear Medicine, Leiden UMC, Leiden, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

56

Objectives: In the past, large retrospective studies have shown that recurrences will frequently occur more than five years after initial treatment of differentiated thyroid carcinoma. The objective of this study was to study the recurrence rate and –time in patients with differentiated thyroid carcinoma who underwent total thyroidectomy, received I-131 ablation, had negative TSH-stimulated Tg-levels and a negative I-131 whole body scan (WBS) at the first follow-up after ablation. Methods: Retrospective data from 3 hospitals from 1980 (1 hospital) or 1990 (2 hospitals) onward on initial treatment and follow-up of patients who received I-131 ablation for differentiated thyroid carcinoma were pooled. Ablation dosages varied from 1110 to 5550 MBq. 3-12 months after ablation patients returned for follow-up with an I-131 WBS (185-370 MBq) and TSH-stimulated Tg-measurement, and were followed again with I-131 WBS and TSH-stimulated at various intervals after that. Patients who tested positive for Tg-antibodies were excluded from the analysis if Tg-levels and the I-131 WBS were negative. Results: 456 patients were included. 10 patients (2.2%) developed a recurrence after an average interval of 32 months (range: 14-58 months) following administration of the ablative dosage of I-131. Recurrence was first discovered by Tg-measurement during suppression in 5 patients, by TSH-stimulated Tg-measurement in 4 patients, and by detection of a pathologic lymph node in 1 patient. Initial staging of the patients who developed a recurrence according to the TNM system was T1N0 in 1 patient, T2N0 in five patients, T3N0 in one patient, T4N0 in one patient and T1N1 in 1 patient. Conclusions: In differentiated thyroid carcinoma patients who had a negative first follow-up I-131 WBS and negative concurrent TSH-stimulated Tg-levels after I-131 ablation, recurrence is a rare event, and in our population never occurs more than 5 years after initial treatment. Beyond the first follow-up after ablation, I-131 WBS seems to have no additional diagnostic value.

  • Society of Nuclear Medicine, Inc.
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 48, Issue supplement 2
May 1, 2007
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Absence of late recurrences in patients with a negative first follow-up after I-131 ablation for differentiated thyroid carcinoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Absence of late recurrences in patients with a negative first follow-up after I-131 ablation for differentiated thyroid carcinoma
Frederik Verburg, Christian Dueren, Robbert Verkooijen, Markus Luster, Johannes van Isselt, Christoph Reiners, Marcel Stokkel
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 17P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Absence of late recurrences in patients with a negative first follow-up after I-131 ablation for differentiated thyroid carcinoma
Frederik Verburg, Christian Dueren, Robbert Verkooijen, Markus Luster, Johannes van Isselt, Christoph Reiners, Marcel Stokkel
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 17P;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties: Endocrinology

  • A comparison of the psychological status in the patients with hyperthyroidism before and after treatment with radioiodine-131
  • The frequency of vomiting after outpatient I-131 therapy (tx) in patients (pts) with well-differentiated thyroid cancer (WDTC)
  • Low dose I-123 MIBG diagnostic scan is inferior to I-131 MIBG post-treatment scan in detection of neuroblastoma
Show more General Clinical Specialties: Endocrinology

Thyroid Cancer Updates II

  • Has come the day to do away with thyroid remnant ablation targeting 300 gray (Gy)?
  • A relationship between F-18 FDG hypermetabolism and progression of pulmonary nodular disease in differentiated thyroid carcinoma
  • Feasibility of an abbreviated protocol for dosimetry-guided I-131 therapy
Show more Thyroid Cancer Updates II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire